AIGH Capital Management LLC Has $4.22 Million Stock Position in PolyPid Ltd. $PYPD

Key Points

• AIGH Capital Management LLC increased its stake in PolyPid Ltd. by 27% in Q2, now holding approximately $4.22 million worth of stock, making it the firm's 21st largest position.
• PolyPid reported a larger-than-expected loss of ($0.78) EPS for the most recent quarter, missing analysts' estimates and indicating ongoing challenges for the company.
• Despite recent losses, multiple analysts maintain a buy rating on PolyPid with price targets ranging from $12.40 to $13.00, reflecting optimism about its future performance.

AIGH Capital Management LLC grew its position in PolyPid Ltd. (NASDAQ:PYPD - Free Report) by 27.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,194,108 shares of the company's stock after buying an additional 253,727 shares during the period. PolyPid makes up 1.9% of AIGH Capital Management LLC's portfolio, making the stock its 21st largest position. AIGH Capital Management LLC owned approximately 11.72% of PolyPid worth $4,215,000 at the end of the most recent quarter.

PolyPid Trading Down 2.4%

Shares of NASDAQ PYPD opened at $3.27 on Monday. The firm has a market cap of $51.99 million, a PE ratio of -0.85 and a beta of 1.50. PolyPid Ltd. has a 1-year low of $2.30 and a 1-year high of $3.93. The company has a fifty day moving average price of $3.41 and a 200 day moving average price of $3.22.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.25). Equities research analysts forecast that PolyPid Ltd. will post -1.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Roth Capital reissued a "buy" rating on shares of PolyPid in a report on Thursday, August 14th. Craig Hallum reissued a "buy" rating and issued a $13.00 price target (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. Wall Street Zen raised shares of PolyPid from a "sell" rating to a "hold" rating in a report on Friday, September 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of PolyPid in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of PolyPid in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.40.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

Want to see what other hedge funds are holding PYPD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PolyPid Ltd. (NASDAQ:PYPD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.